Systemic Lupus Erythematosus

Written by Gizem Güler

Systemic lupus erythematosus (SLE) is an autoimmune disease that is caused by chronic inflammation and tissue damage due to autoreactive antibodies. The major pathogenic cellular characteristic is abnormal B cell activity. The secreted auto-reactive antibodies are directed toward cellular components and can cause multiorgan damage by immune complex deposition and inflammation within affected tissues. Hereditary mutations in human leukocyte antigen (HLA) genes further contribute to the dysregulated signaling between T helper cells and B cells. SLE is most prevalent in adult women, while various genetic and environmental factors play a role in the disease process. Non-specific SLE can vary from systemic symptoms to musculoskeletal or dermatological features. Clinical features are reflected both in manifestations of active lupus, caused by inflammation events, and chronic organ damages. There are various therapeutic medications for SLE that can prevent flares, as well as reduce disease severity and duration. Currently used treatment methods include disease-modifying antirheumatic drugs (DMARDs), immune cell targeted therapies and anti-cytokine medications.

Clinical Features



Cellular Characteristics





  1. "SLE: Clinical presentations. Smith, Gordon. Autoimmunity Reviews. Volume 10, Issue 1, November 2010, Pages 43-45."
  2. "Clinical Features of Systemic Lupus Erythematosus Patients Complicated With Evans Syndrome. Zhang, Wu. Medicine (Baltimore). 2016 Apr; 95(15): e3279."
  3. "Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Heinlen, McClain. Arthritis & Rheumathology. Volume56, Issue7July 2007. Pages 2344-2351."
  4. "Epdemiology of SLE. Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Expert Rev Clin Immunol. 2017 Aug;13(8):799-814."
  5. "The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W.Rheumatology (Oxford).2017 Nov 1;56(11):1945-1961"
  6. "Current and Novel Therapeutics in Treatment of SLE. Diamond et al. J Allergy Clin Immunol. 2011 Feb; 127(2): 303–314. "
  7. "Abnormal B Cell Development in Systemic Lupus Erythematosus. Karrar, Graham et al.Arthritis Rheumatol. 2018 Apr; 70(4): 496–507"
  8. "The Pathogenesis of Systemic Lupus Erythematosus. Choi, Kim, Kraft et al. Curr Opin Immunol. 2012 Dec; 24(6): 651–657. "
  9. "The genetics of lupus: a functional perspective. Guerra, Cunninghame, Graham et al. Arthritis Research Therapy. BioMed Central Ltd 2012. Published: 29 May 2012."
  10. "Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Shao, Cohen et al. Arthritis Res Ther.2011; 13(1): 202. Published online 2011 Feb 28."
  11. "Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. Pathak, Mohan et al. Arthritis Res Ther. 2011; 13(5): 241. "
  12. "Genetic Factors Predisposing to Systemic Lupus Erythematosus and Lupus Nephritis. Ramos, Brown et al. Semin Nephrol. 2010 Mar; 30(2): 164–176. "